Key result
This review discusses the clinical management of arrhythmogenic cardiomyopathy, with particular reference to diagnosis, risk stratification, therapy, and indications for physical activity.
This paper provides a comprehensive review of the clinical management of arrhythmogenic cardiomyopathy, focusing on diagnosis, risk stratification, therapy, and lifestyle indications.
Answers are grounded in this paper and cite their sources.
May guide arrhythmogenic cardiomyopathy management discussions; leaves open need for prospective validation of activity recommendations.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disorder with an autosomal dominant inheritance and incomplete penetrance. It predominantly affects the right ventricle (RV), predisposing to the origin of ventricular arrhythmias and sudden death (SD). The structural basis of the disease consists of the progressive loss of myocardium with fibro-adipose replacement. ARVC is a “desmosomes” disease involving mutations of proteins such as placoglobin, desmoplachine, placophylline, desmoglein, and desmocollin. In the “classical” form, the disease mainly implicates the RV chamber, while the left ventricle (LV) is involved in advanced stages. Genotype-phenotype correlation studies have identified some phenotypic variants characterized by an early participation of the LV, which can proceed in parallel toward the two ventricles (“biventricular” variant) or prevails over the RV (variant to “left dominance”). These data led to the evolution of the initial definition of ARVC, which is currently considered a genetic disease of both ventricles and, therefore, deserves the denomination “arrhythmogenic cardiomyopathy”. Many aspects of diagnosis, treatment, and indications for a correct lifestyle are important in sports medicine. This paper will discuss the clinical management of ARVC, with particular reference to diagnosis, risk stratification, therapy, and indications for physical activity.
No takes yet. Share an insight, caveat, or question.
Stefani et al. (2018) conducted a review in Arrhythmogenic right ventricular cardiomyopathy (ARVC). This review discusses the clinical management of arrhythmogenic cardiomyopathy, with particular reference to diagnosis, risk stratification, therapy, and indications for physical activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: